Consumer Preferences for Attributes of Influenza Vaccines in the United States: Results from a Discrete-Choice Experiment Study
Speaker(s)
Poulos C1, Leach CA1, Kent C1, Rudin D2, Buck P3, Ghaswalla P2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Moderna, Inc., Cambridge, MA, USA, 3Moderna, Inc., Philadelphia, PA, USA
Presentation Documents
OBJECTIVES: Quantify preferences for influenza vaccine attributes among consumers in the United States (US).
METHODS: Using a discrete-choice experiment, US adults were presented with a series of experimentally designed pairs of hypothetical influenza vaccines comprising five attributes with varying levels: absolute vaccine efficacy (AVE) (15%-60% of influenza infections prevented), hospitalization prevention (same as most other vaccines, more than most other vaccines), durability (protection fades within 6 months, constant protection for at least 6 months), and side effects (risk of moderate-to-severe injection site reactions [ISR] [0%-50%] and risk of flu-like symptoms [FLS] due to the vaccine [0%-60%]). In each choice question, respondents selected the preferred vaccine or “no flu vaccine.”
Random-parameters logit analysis results were used to calculate conditional relative attribute importance (CRI) out of 100% and maximum acceptable risks of vaccine side effects in exchange for improvements in vaccine efficacy.RESULTS: The sample included 400 respondents aged 18-64 years and 201 respondents aged ≥ 65 years. Half had at least one non-age risk factor for severe influenza.
On average, consumers preferred influenza vaccination to opting out of vaccination. Consumers placed greatest importance on avoiding risk of FLS (CRI, 40%), followed by increasing AVE (CRI, 36%) and avoiding ISR risk (CRI, 21%). On average, hospitalization prevention and durability had no influence on vaccine choice. Consumers were less tolerant of FLS than ISR. For an improvement in AVE from 15% to 25%, consumers would be willing to accept a 34% risk of ISR or a 19% risk of FLS. For an improvement in AVE from 25% to 50%, consumers would be willing to accept a 31% risk of ISR or a 16% risk of FLS.CONCLUSIONS: Adults in the US were willing to accept increases in vaccine-related risks for improved AVE, and they were more tolerant of ISR risks than FLS risks.
Code
PCR47
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines